DE69936352D1 - Stabilisierung von rapamycinen oder rapamycinderivaten - Google Patents

Stabilisierung von rapamycinen oder rapamycinderivaten

Info

Publication number
DE69936352D1
DE69936352D1 DE69936352T DE69936352T DE69936352D1 DE 69936352 D1 DE69936352 D1 DE 69936352D1 DE 69936352 T DE69936352 T DE 69936352T DE 69936352 T DE69936352 T DE 69936352T DE 69936352 D1 DE69936352 D1 DE 69936352D1
Authority
DE
Germany
Prior art keywords
rapamycin
stabilization
derivatives
rapamycin derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69936352T
Other languages
English (en)
Other versions
DE69936352T3 (de
DE69936352T2 (de
Inventor
Francois Navarro
Samuel Petit
Guy Stone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69936352(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE69936352D1 publication Critical patent/DE69936352D1/de
Application granted granted Critical
Publication of DE69936352T2 publication Critical patent/DE69936352T2/de
Publication of DE69936352T3 publication Critical patent/DE69936352T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DE69936352T 1998-12-07 1999-12-06 Stabilisierung von rapamycinen oder rapamycinderivaten Expired - Lifetime DE69936352T3 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9826882.4A GB9826882D0 (en) 1998-12-07 1998-12-07 Organic compounds
GB9826882 1998-12-07
GBGB9904934.8A GB9904934D0 (en) 1998-12-07 1999-03-04 Organic compounds
GB9904934 1999-03-04
EP99959381A EP1137439B2 (de) 1998-12-07 1999-12-06 Stabilisierung von rapamycinen oder rapamycinderivaten
PCT/EP1999/009521 WO2000033878A2 (en) 1998-12-07 1999-12-06 Stabilization of macrolides

Publications (3)

Publication Number Publication Date
DE69936352D1 true DE69936352D1 (de) 2007-08-02
DE69936352T2 DE69936352T2 (de) 2008-02-14
DE69936352T3 DE69936352T3 (de) 2012-05-03

Family

ID=26314797

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69936352T Expired - Lifetime DE69936352T3 (de) 1998-12-07 1999-12-06 Stabilisierung von rapamycinen oder rapamycinderivaten

Country Status (38)

Country Link
US (5) US6605613B2 (de)
EP (4) EP2279751A3 (de)
JP (3) JP3805625B2 (de)
KR (2) KR20060096477A (de)
CN (2) CN1876657B (de)
AR (3) AR026102A1 (de)
AT (1) ATE365051T1 (de)
AU (1) AU759219B2 (de)
BE (1) BE1012869A3 (de)
BR (1) BR9915986A (de)
CA (3) CA2351580C (de)
CO (1) CO4980847A1 (de)
CY (1) CY1106870T1 (de)
CZ (2) CZ302210B6 (de)
DE (1) DE69936352T3 (de)
DK (1) DK1137439T4 (de)
ES (1) ES2288033T5 (de)
FR (1) FR2786771B1 (de)
GB (2) GB9826882D0 (de)
HK (1) HK1038889B (de)
HU (2) HU228939B1 (de)
ID (1) ID29250A (de)
IL (1) IL143092A0 (de)
IT (1) IT1319701B1 (de)
MY (2) MY127579A (de)
NO (2) NO332698B1 (de)
NZ (2) NZ511936A (de)
PE (1) PE20001333A1 (de)
PL (2) PL208854B1 (de)
PT (1) PT1137439E (de)
RU (1) RU2243769C2 (de)
SG (1) SG151072A1 (de)
SI (1) SI1137439T2 (de)
SK (2) SK286688B6 (de)
TR (2) TR200201428T2 (de)
TW (2) TWI270550B (de)
WO (1) WO2000033878A2 (de)
ZA (1) ZA200104360B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7452692B2 (en) 2002-02-13 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Method for extracting a macrolide from biomatter
ZA200406350B (en) 2002-02-13 2006-11-29 Teva Gyogyszergyar Reszveny Tarsasag Method for extracting a macrolide from biomatter
DK1553940T3 (da) 2002-07-30 2008-06-02 Wyeth Corp Patenterale formuleringer indeholdende en rapamycin-hydroxyester
TW200504079A (en) 2003-03-31 2005-02-01 Biogal Gyogyszergyar Crystallization and purification of macrolides
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220357B2 (en) 2003-07-24 2007-05-22 Teva Gyógyszergyár Zártkörúen Múkó´dó´Résvénytársaság Method of purifying macrolides
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
CN1889994A (zh) * 2003-12-10 2007-01-03 艾克若克斯Dds有限公司 伴随透皮或局部药物输送的不希望的效果的治疗方法
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
MX2007003731A (es) * 2004-09-29 2007-08-14 Johnson & Johnson Formas de dosis farmaceuticas de compuestos similares a rapamicina amorfos estables.
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
CN101340901A (zh) * 2005-12-20 2009-01-07 惠氏公司 通过控制药物物质杂质控制cci-779剂型稳定性
EP2001438A2 (de) * 2006-02-09 2008-12-17 Macusight, Inc. Stabile formulierungen sowie verfahren zu ihrer herstellung und verwendung
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
AU2011260016B2 (en) 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
JP2013529224A (ja) * 2010-06-07 2013-07-18 テリック，インコーポレイテッド 結晶性エザチオスタット塩酸塩非溶媒和物
US9321782B2 (en) * 2010-08-04 2016-04-26 Meril Life Sciences Pvt. Ltd. Process for preparation of novel 42-O-(heteroalkoxyalkyl) rapamicin compounds with anti-proliferative properties
ES2753529T3 (es) 2010-11-19 2020-04-13 Biocon Ltd Procesos para la preparación de everolimús y productos intermedios del mismo
US8809562B2 (en) 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
WO2013022201A1 (en) * 2011-08-11 2013-02-14 Dong-A Pharm. Co., Ltd. Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
US9610385B2 (en) 2013-03-07 2017-04-04 Abbott Cardiovascular Systems Inc. Method of fabricating an implantable medical device comprising a rapamycin derivative
IN2013MU02532A (de) 2013-07-31 2015-06-26 Sahajanand Medical Technologies Pvt Ltd
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
EP3329916A4 (de) 2015-07-28 2019-03-20 Nippon Kayaku Kabushiki Kaisha Pharmazeutische zusammensetzung mit rapamycin oder derivat davon und herstellungsverfahren dafür
EP3342410A4 (de) * 2015-08-28 2019-04-24 Nippon Kayaku Kabushiki Kaisha Pharmazeutische zusammensetzung mit rapamycin oder derivat davon
US20190038605A1 (en) * 2015-09-18 2019-02-07 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
EP3466424A1 (de) 2016-05-27 2019-04-10 Nippon Kayaku Kabushiki Kaisha Pharmazeutische zusammensetzung mit rapamycin oder derivat davon
KR102051806B1 (ko) * 2018-01-12 2019-12-04 주식회사 종근당 에베로리무스를 포함하는 안정화된 약제학적 제제
EP4126882A1 (de) * 2020-03-27 2023-02-08 Boston Scientific Scimed Inc. Verfahren zur kristallisierung von arzneimitteln
JP2023028473A (ja) * 2021-08-19 2023-03-03 日本マイクロバイオファーマ株式会社 エベロリムスの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3996355A (en) 1975-01-02 1976-12-07 American Home Products Corporation Permanent suspension pharmaceutical dosage form
US4049128A (en) 1976-11-18 1977-09-20 Westinghouse Air Brake Company Control system for automatic railway car coupler
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
JPH01249651A (ja) † 1988-02-18 1989-10-04 E I Du Pont De Nemours & Co セラミツク／蒸留可能な結合剤組成物
KR0159766B1 (ko) * 1989-10-16 1998-12-01 후지사와 토모키치로 양모제 조성물
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
FI97472C (fi) 1991-05-07 1996-12-27 American Home Prod Menetelmä terapeuttisesti käyttökelpoisten rapamysiinijohdannaisten valmistamiseksi anti-inflammatorisina ja antifungaalisina aineina
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
EP0593227B1 (de) 1992-10-13 2006-03-22 Wyeth Carbamate von Rapamycin
DK0833828T3 (da) 1995-06-09 2003-03-17 Novartis Ag Rapamycinderivater
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
CA2261666C (en) * 1996-07-30 2010-09-14 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
US6362264B1 (en) * 1996-12-20 2002-03-26 Ck Witco Corporation Stabilizer for food contact and medical grade PVC
WO1998033482A1 (en) 1997-02-04 1998-08-06 Abbott Laboratories Pain reducing parenteral liposome formulation

Also Published As

Publication number Publication date
US7297703B2 (en) 2007-11-20
HUP0104489A3 (en) 2004-05-28
ZA200104360B (en) 2002-01-16
CA2351580C (en) 2012-03-20
CA2351580A1 (en) 2000-06-15
US20050107418A1 (en) 2005-05-19
NO332698B1 (no) 2012-12-10
PL208854B1 (pl) 2011-06-30
EP1743657A3 (de) 2007-03-28
JP5043308B2 (ja) 2012-10-10
NO334612B1 (no) 2014-04-22
GB9826882D0 (en) 1999-01-27
ES2288033T5 (es) 2012-04-10
EP1743657A2 (de) 2007-01-17
HK1038889A1 (en) 2002-04-04
IL143092A0 (en) 2002-04-21
US7741338B2 (en) 2010-06-22
AU1657300A (en) 2000-06-26
US6605613B2 (en) 2003-08-12
IT1319701B1 (it) 2003-10-27
FR2786771B1 (fr) 2002-12-27
US20020032213A1 (en) 2002-03-14
US7572804B2 (en) 2009-08-11
CN1876657A (zh) 2006-12-13
US20080161334A1 (en) 2008-07-03
HUP0104489A2 (hu) 2002-03-28
CN1374872A (zh) 2002-10-16
CO4980847A1 (es) 2000-11-27
US6852729B2 (en) 2005-02-08
DK1137439T4 (da) 2012-03-19
SI1137439T1 (sl) 2008-06-30
NZ527781A (en) 2004-11-26
JP2005200429A (ja) 2005-07-28
EP1137439B1 (de) 2007-06-20
AR048073A2 (es) 2006-03-29
US20030191148A1 (en) 2003-10-09
EP1137439A2 (de) 2001-10-04
NO20012424L (no) 2001-05-16
PL196627B1 (pl) 2008-01-31
NZ511936A (en) 2003-10-31
CZ303006B6 (cs) 2012-02-22
CA2651609A1 (en) 2000-06-15
MY120594A (en) 2005-11-30
HK1038889B (zh) 2008-01-25
HU228939B1 (en) 2013-07-29
SK287325B6 (sk) 2010-07-07
CA2732620C (en) 2013-08-06
AR026102A1 (es) 2003-01-29
ITMI992520A1 (it) 2001-06-02
TR200201428T2 (tr) 2002-12-23
ITMI992520A0 (it) 1999-12-02
TR200101416T2 (tr) 2002-01-21
CZ302210B6 (cs) 2010-12-22
ES2288033T3 (es) 2007-12-16
GB9904934D0 (en) 1999-04-28
JP2002531527A (ja) 2002-09-24
KR20060096477A (ko) 2006-09-11
CN1876657B (zh) 2013-01-09
MY127579A (en) 2006-12-29
WO2000033878A2 (en) 2000-06-15
HU230174B1 (hu) 2015-09-28
ATE365051T1 (de) 2007-07-15
BE1012869A3 (fr) 2001-04-03
PE20001333A1 (es) 2000-12-12
JP3805625B2 (ja) 2006-08-02
CY1106870T1 (el) 2012-09-26
DK1137439T3 (da) 2007-09-10
DE69936352T3 (de) 2012-05-03
US20090270441A1 (en) 2009-10-29
DE69936352T2 (de) 2008-02-14
EP2279751A3 (de) 2011-02-16
NO20121113L (no) 2001-05-16
KR100695834B1 (ko) 2007-03-19
CZ20012001A3 (cs) 2001-09-12
FR2786771A1 (fr) 2000-06-09
EP2269651A3 (de) 2011-03-09
TWI248938B (en) 2006-02-11
JP2006111637A (ja) 2006-04-27
TWI270550B (en) 2007-01-11
BR9915986A (pt) 2001-09-04
AU759219B2 (en) 2003-04-10
AR054444A2 (es) 2007-06-27
SG151072A1 (en) 2009-06-29
NO20012424D0 (no) 2001-05-16
PT1137439E (pt) 2007-09-25
KR20010101128A (ko) 2001-11-14
EP2279751A2 (de) 2011-02-02
ID29250A (id) 2001-08-16
SK7662001A3 (en) 2001-12-03
WO2000033878A3 (en) 2000-11-02
EP2269651A2 (de) 2011-01-05
TW200540179A (en) 2005-12-16
SK286688B6 (sk) 2009-03-05
CN1261163C (zh) 2006-06-28
JP5165199B2 (ja) 2013-03-21
CA2732620A1 (en) 2000-06-15
PL348333A1 (en) 2002-05-20
EP1137439B2 (de) 2011-11-23
RU2243769C2 (ru) 2005-01-10
SI1137439T2 (sl) 2012-05-31

Similar Documents

Publication Publication Date Title
DE69936352D1 (de) Stabilisierung von rapamycinen oder rapamycinderivaten
ATE222256T1 (de) Polymorphe form von clopidogrel-hydrogenosulfat
DE69941116D1 (de) G von gdf-8
ID29021A (id) Komposisi galantamina pelepasan terkontrol
IT1295008B1 (it) Combinazione di stabilizzanti
DE69928195D1 (de) Komplettierung von Untrerdruck-Bohrlöchern
PT1161420E (pt) Fungicidas de pirazol-carboxanilidas
DE60028307D1 (de) Eliminierung von interferenzsignalen
DE50010774D1 (de) Anlage zur bearbeitung von wafern
DE69931983D1 (de) Stabilisator
DE50013866D1 (de) Anlage zur bearbeitung von wafern
DE50013163D1 (de) Anlage zur bearbeitung von wafern
PT1140924E (pt) Derivados de piperazina
IT1294339B1 (it) Miscele di stabilizzanti
DE69806558D1 (de) Stabilisierung von 3-Isothiazolonlösungen
FI955164A0 (fi) Heterosykliset johdannaiset
PT1246817E (pt) Derivados de 4-fenil-1-piperazinilo, -piperidinilo e -tetra-hidropiridilo
IT1293824B1 (it) Miscele di stabilizzanti
DK1067958T3 (da) Behandling af hjertehypertrofi
ATE222456T1 (de) Stabilisierung von isothiazolonen
DE69908614D1 (de) Herstellung von n-substituierten-hydroxycycloalkylamin-derivaten
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
DE69910409D1 (de) Disaccharide-derivate
NO20003529D0 (no) Behandling av dyskinesi

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN

R102 Epo decision maintaining patent in amended form now final

Ref document number: 1137439

Country of ref document: EP

R102 Epo decision maintaining patent in amended form now final

Ref document number: 1137439

Country of ref document: EP

Effective date: 20111123